GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (TSX:IN) » Definitions » Shiller PE Ratio

InMed Pharmaceuticals (TSX:IN) Shiller PE Ratio : (As of May. 06, 2024)


View and export this data going back to 2014. Start your Free Trial

What is InMed Pharmaceuticals Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


InMed Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for InMed Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Shiller PE Ratio Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InMed Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InMed Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, InMed Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Shiller PE Ratio falls into.



InMed Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

InMed Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, InMed Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/125.4675*125.4675
=0.000

Current CPI (Dec. 2023) = 125.4675.

InMed Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.100 98.604 -0.127
201406 -0.889 99.473 -1.121
201409 -0.651 99.394 -0.822
201412 -0.328 98.367 -0.418
201503 -1.314 99.789 -1.652
201506 -0.706 100.500 -0.881
201509 -0.326 100.421 -0.407
201512 -0.326 99.947 -0.409
201603 -0.336 101.054 -0.417
201606 -0.332 102.002 -0.408
201609 -0.329 101.765 -0.406
201612 -0.327 101.449 -0.404
201703 -0.331 102.634 -0.405
201706 -0.700 103.029 -0.852
201709 -0.327 103.345 -0.397
201712 -0.335 103.345 -0.407
201803 -0.330 105.004 -0.394
201806 -0.634 105.557 -0.754
201809 -0.666 105.636 -0.791
201812 -0.651 105.399 -0.775
201903 -0.661 106.979 -0.775
201906 -0.949 107.690 -1.106
201909 -0.715 107.611 -0.834
201912 -0.632 107.769 -0.736
202003 -0.650 107.927 -0.756
202006 -0.360 108.401 -0.417
202009 -0.410 108.164 -0.476
202012 -0.474 108.559 -0.548
202103 0.000 110.298 0.000
202106 0.000 111.720 0.000
202109 0.000 112.905 0.000
202112 0.000 113.774 0.000
202203 0.000 117.646 0.000
202206 0.000 120.806 0.000
202209 0.000 120.648 0.000
202212 0.000 120.964 0.000
202303 0.000 122.702 0.000
202306 0.000 124.203 0.000
202309 0.000 125.230 0.000
202312 0.000 125.468 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


InMed Pharmaceuticals  (TSX:IN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


InMed Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (TSX:IN) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (TSX:IN) Headlines

No Headlines